Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2927088 in Advanced NSCLC With EGFR/HER2 Mutations
NCT05099172Phase 2Recruiting
- Sponsor
- Bayer
- Start
- Oct 2021
- Primary completion
- Dec 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 16
01
Overview
A Phase 2 trial of sevabertinib in non-small cell lung cancer (NSCLC), sponsored by Bayer. Started Oct 2021; status: recruiting.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05099172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099172.